Sanuwave completes patient follow-up in phase 3 trial of diabetic foot ulcer treatment
from Ortho Super Site
Sanuwave Health, Inc. a medical technology company focused on noninvasive, biological-response activating devices in regenerative medicine, announced in a press release the completion of patient follow-up in the company's pivotal phase 3, Investigational Device Exemption (IDE) clinical trial with dermaPACE for the treatment of diabetic foot ulcers.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063